410 Medical Raises $14M Series B Led by Hatteras to Expand LifeFlow
410 Medical , a Durham, North Carolina medical device company behind the LifeFlow rapid infusion platform, closed a $14M Series B led by Hatteras Venture Partners. The round included Orlando Health Ventures, Ballad Ventures, OSF HealthCare, WakeMed, Rex Health Ventures, CU Healthcare Innovation Fund, Sarnova, and other strategic partners.
The capital is aimed at expanding access to LifeFlow technologies in emergency and critical care settings. That matters because 410 Medical is not chasing a vague healthcare platform story. It is building around a narrow clinical workflow where speed, control, and simplicity can shape what happens when a patient is unstable.
What Happened
410 Medical announced a $14M Series B financing to support commercialization and broader deployment of its LifeFlow portfolio. The official financing included Orlando Health Ventures, Ballad Ventures, OSF HealthCare, WakeMed, Rex Health Ventures, CU Healthcare Innovation Fund, Sarnova, and other strategic participants alongside lead investor Hatteras Venture Partners.
Founded in 2013, 410 Medical develops rapid infusion medical devices for emergency and critical care. Its LifeFlow and LifeFlow PLUS systems are hand-operated rapid infusers designed to help clinicians deliver fluids and blood products quickly while maintaining control over volume and infusion rate. The platform is intended for emergency departments, ICUs, transport medicine, and military care settings.
Why This Matters
Healthcare technology loves to talk about artificial intelligence, predictive analytics, and digital transformation. Those markets are real, but emergency medicine still depends on clinicians making high-pressure decisions in physical environments where every extra step creates friction.
410 Medical's approach is refreshingly direct because LifeFlow improves a workflow clinicians already understand. The device is designed for situations such as hemorrhagic shock, severe sepsis, trauma, and cardiac arrest, where rapid fluid or blood administration can become part of an urgent resuscitation response. The value proposition is not more software around the clinician. It is a practical tool inside the moment.
Market Context
Emergency and critical care remain among healthcare's most operationally demanding environments. Hospitals continue dealing with staffing pressure, rising patient acuity, procurement scrutiny, and the constant need to improve outcomes without adding unnecessary complexity at the bedside.
That is where 410 Medical's investor mix becomes important. Strategic health systems do not evaluate acute-care technology from a spreadsheet alone. They bring operational context, clinician experience, and implementation realities into the diligence process, making their participation a stronger signal than a conventional healthcare venture round.
Competitive Landscape
Medical device companies serving emergency medicine compete on a different field than software startups. Regulatory clearance, clinician trust, procurement cycles, training requirements, and real-world performance matter more than a polished demonstration or a clever narrative.
LifeFlow enters a market where hospitals already have established resuscitation protocols and clinical workflows. That means adoption depends less on replacing clinical judgment and more on helping experienced teams execute familiar interventions faster and with greater control. In that kind of market, practical engineering can be more defensible than theatrical innovation.
What This Signals
The round suggests healthcare investors remain willing to fund companies solving specific, high-acuity clinical problems. It also shows capital becoming more closely aligned with clinical validation, particularly when health systems invest alongside venture firms in products built for their own operating environments.
For founders, the lesson is straightforward. 410 Medical did not begin with a technology searching for a market. Founder Dr. Mark D. Piehl's clinical experience helped shape the LifeFlow concept, and the company has built around a problem emergency and critical care teams recognize immediately.
The Bigger Industry Shift
Healthcare is entering a period where execution matters more than storytelling. Hospitals are evaluating technology based on workflow fit, clinical usefulness, and the likelihood that a product can survive procurement and frontline scrutiny.
410 Medical's $14M Series B fits that shift. The broader market may continue chasing large platform narratives, but companies solving precise clinical problems can still build durable momentum. In emergency care, the best innovation is often the one that gets out of the way and helps the room move faster.
Healthcare funding, last 30 days
DevCuration's funding database tracked 15 Healthcare rounds totaling $1B in disclosed capital over the past 30 days. Recent deals we covered:
- Corner Health Raises $32.5M for Independent Primary CareSeries A · $32.5M · Jul 15
- Momentum Life Sciences Secures Parthenon Capital InvestmentStrategic Growth Investment · Jul 14
- Regal Healthcare Capital Partners Closes $610M RHCP IVFund IV · $610M · Jul 12
- Sage Secures $35M Debt Facility to Expand Senior Care InfrastructureDebt · $35M · Jul 11
- Allotera Therapeutics Raises $35M for CAR-T TherapySeries C · $35M · Jul 11
Frequently Asked Questions
Why does 410 Medical's Series B matter for critical care technology?
The round points to continued investor interest in practical medical devices that improve acute-care workflows. 410 Medical is focused on rapid infusion in emergency and critical care settings, where speed, control and ease of use can matter more than broad platform claims.
What is LifeFlow?
LifeFlow is 410 Medical's rapid infusion technology platform. Public company materials describe LifeFlow and LifeFlow PLUS as hand-operated systems designed to help clinicians quickly deliver fluids and blood products in emergency departments, ICUs, transport medicine and related care settings.
What does the investor syndicate signal?
The syndicate includes venture investors and multiple health-system or strategic healthcare participants. That mix suggests the product is being evaluated not only as a financial investment, but also through the lens of clinical workflow relevance and real-world adoption.
How is this different from broader digital health funding?
Many digital health rounds center on software layers, analytics or administrative workflow. 410 Medical is a medical device company focused on a physical intervention point in acute care, which means adoption depends on clinician trust, procurement fit, regulatory discipline and bedside utility.
What should operators and investors watch next?
The key signals are broader LifeFlow deployment, continued health-system adoption, clinical evidence, distribution expansion and whether 410 Medical can turn a focused acute-care workflow into durable commercial momentum.
